Extract to table

2 (Item 7) will be updated to incorporate CLARION-3R data (upon availability of top-line results and the clinical study report), any intervening changes to FDA labeling requirements or format specifications, any revisions to the boxed Warning or other safety-related labeling arising from post-marketing data, and any changes to the Velonatib rheumatoid arthritis labeling that occurred during the dormancy period and that must be reflected in the psoriasis sNDA labeling supplement